Wall Street analysts predict that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report sales of $8.00 million for the current quarter, according to Zacks. Five analysts have made estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $4.10 million and the highest is $13.42 million. Five Prime Therapeutics reported sales of $13.22 million during the same quarter last year, which indicates a negative year-over-year growth rate of 39.5%. The firm is expected to report its next quarterly earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full-year sales of $52.48 million for the current fiscal year, with estimates ranging from $49.94 million to $53.84 million. For the next year, analysts forecast that the firm will post sales of $28.86 million, with estimates ranging from $7.30 million to $60.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. The business had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $7.45 million.

Several analysts have recently commented on FPRX shares. Wells Fargo & Co decreased their price objective on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating for the company in a report on Thursday, August 9th. Leerink Swann assumed coverage on Five Prime Therapeutics in a research note on Thursday, September 13th. They issued an “outperform” rating and a $24.00 target price for the company. BidaskClub lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 29th. Citigroup reduced their target price on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 20th. Finally, Wedbush raised their target price on Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a research note on Friday, August 10th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $29.67.

Shares of FPRX opened at $11.26 on Wednesday. Five Prime Therapeutics has a 12 month low of $10.35 and a 12 month high of $27.61. The firm has a market cap of $410.34 million, a PE ratio of -2.09 and a beta of 3.23.

Hedge funds have recently modified their holdings of the stock. Price Capital Management Inc. purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $118,000. Xact Kapitalforvaltning AB purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $145,000. Granite Investment Partners LLC purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $240,000. MetLife Investment Advisors LLC raised its stake in Five Prime Therapeutics by 48.7% in the 2nd quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 6,535 shares during the last quarter. Finally, Alambic Investment Management L.P. purchased a new position in Five Prime Therapeutics in the 2nd quarter worth $351,000. Institutional investors own 83.03% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.